Araris Biotech AG

Araris Biotech AG, a spin-off of the Paul Scherrer Institute (PSI) and ETH Zurich, is developing novel antibody-drug conjugates for targeted chemotherapies against cancer. Araris’ technology makes it possible to bind active substances stably to antibodies so that the often very aggressive cancer drugs only take effect in the body where they are actually supposed to. The aim of Araris is to make the treatment of cancer more effective and at the same time gentler for patients.